Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma

Trial Profile

Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Galunisertib (Primary) ; Lomustine
  • Indications Glioma
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly
  • Most Recent Events

    • 06 Jan 2017 Planned End Date changed from 1 Sep 2016 to 1 Oct 2018.
    • 04 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2016 as per ClinicalTrials.gov record.
    • 13 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top